Latest News on QTRX

Financial News Based On Company


Advertisement
Advertisement

Quanterix Corporation FY26 Results: Sales guidance affirmed at $142M-$146M

https://scanx.trade/stock-market-news/companies/quanterix-corporation-fy26-results-sales-guidance-affirmed-142m-146m/56555447
Quanterix Corporation has reaffirmed its full-year fiscal 2026 sales guidance, projecting revenue between $142 million and $146 million, which aligns closely with the analyst consensus of $143.357 million. This steady forecast indicates the company's confidence in its current operational trends and a cautious revenue trajectory for the upcoming fiscal year. The guidance suggests stable expectations, with the analyst estimate falling within the lower half of the company's projected range.

GeneDx hires Quanterix CEO Everett Cunningham to replace Katherine Stueland, with $20 million in stock awards

https://mlq.ai/news/genedx-hires-quanterix-ceo-everett-cunningham-to-replace-katherine-stueland-with-20-million-in-stock-awards/
GeneDx has announced that Everett Cunningham, previously CEO of Quanterix, will take over as its new chief executive, replacing Katherine Stueland. Cunningham's compensation package includes a $750,000 base salary, a $1.05 million sign-on bonus, and $20 million in stock awards tied to performance hurdles. Quanterix has appointed Jim Gute as interim president and CEO and reaffirmed its financial outlook.

Quanterix CEO Everett Cunningham resigns; James Gute named interim CEO

https://www.tradingview.com/news/tradingview:bf0fecc7e4374:0-quanterix-ceo-everett-cunningham-resigns-james-gute-named-interim-ceo/
Quanterix CEO Everett Cunningham has resigned, with Chief Commercial Officer James Gute stepping in as interim CEO while the company searches for a permanent successor. Cunningham's departure, effective November 18, 2026, was due to accepting another opportunity and was not related to company disagreements. Gute will receive an annualized salary of $750,000 in his interim role.

Quanterix CEO steps down; CCO named interim chief

https://www.streetinsider.com/Corporate+News/Quanterix+CEO+steps+down%3B+CCO+named+interim+chief/27367087.html
Quanterix Corporation announced that Everett Cunningham has stepped down as President and CEO to pursue another opportunity in healthcare. The board has appointed Jim Gute, the company's Chief Commercial Officer, as Interim President and CEO while a search for a permanent replacement is underway. Quanterix also reaffirmed its 2026 financial outlook.

Quanterix appoints Jim Gute as interim CEO as Everett Cunningham steps down

https://www.tradingview.com/news/seekingalpha:bb34a9c41094b:0-quanterix-appoints-jim-gute-as-interim-ceo-as-everett-cunningham-steps-down/
Quanterix announced that Everett Cunningham has resigned as president and CEO and from the board of directors to pursue another opportunity in healthcare, effective immediately. Jim Gute, the company's chief commercial officer, has been appointed interim president and CEO while a search for a permanent replacement is conducted. Cunningham will assist with the transition until December 11, 2026.
Advertisement

Quanterix CEO Everett Cunningham steps down, Jim Gute named interim

https://www.investing.com/news/company-news/quanterix-ceo-everett-cunningham-steps-down-jim-gute-named-interim-93CH-5035989
Quanterix Corporation announced that CEO Everett Cunningham has stepped down immediately to pursue another opportunity in the healthcare sector. The Board has appointed Jim Gute, the company's Chief Commercial Officer, as Interim President and CEO while a search for a permanent replacement is conducted. The company also reaffirmed its financial outlook as provided earlier in November.

Quanterix Announces Leadership Transition Plan

https://www.quantisnow.com/insight/quanterix-announces-leadership-transition-plan-6798118
Quanterix announced that CEO Everett Cunningham has stepped down immediately to take a role elsewhere in healthcare. Chief Commercial Officer Jim Gute has been named interim President and CEO while the company searches for a permanent replacement. Quanterix reaffirmed its 2026 financial outlook, indicating that the leadership change does not alter previous guidance.

Quanterix (QTRX) reports 467 shares delivered or withheld at $2.93 each.

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-8fde257c3ad0.html
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, converted restricted stock units into 1,558 common shares on November 15, 2026. This transaction also included 467 shares delivered or withheld for tax liability or exercise price payment across five transactions, each valued at $2.93 per share. The SEC filing provides details on the vesting schedule of the restricted stock units and the changes in Miller's holdings.

Form 4 Quanterix Corp: James Edward Gute Jr (Chief Commercial Officer) For: 15 September

https://ca.investing.com/news/stock-market-news/form-4-quanterix-corp-james-edward-gute-jr-chief-commercial-officer-for-15-september-93CH-4951073
This article reports on a Form 4 filing for Quanterix Corp, detailing an insider transaction by James Edward Gute Jr, the Chief Commercial Officer. The transaction date is specified as September 15. The article provides only the title of the filing without further details of the transaction.

Earnings Update: Here's Why Analysts Just Lifted Their Quanterix Corporation (NASDAQ:QTRX) Price Target To US$3.17

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qtrx/quanterix/news/earnings-update-heres-why-analysts-just-lifted-their-quanter
Quanterix Corporation recently reported third-quarter results, with revenues exceeding expectations but statutory earnings falling short. Despite an anticipated increase in losses for the next year and a slower revenue growth forecast compared to the industry, analysts have raised their price target for QTRX to US$3.17, suggesting they believe the company's intrinsic value will improve over time. The consensus among three analysts projects revenues of US$156.3m in 2027, with losses per share expected to significantly narrow.
Advertisement

Quanterix Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63033059/quanterix-q3-2026-earnings-call-transcript
Quanterix (NASDAQ: QTRX) reported its third-quarter 2026 financial results, showcasing a 6.3% sequential revenue growth to $35 million, driven by strong performance in the Americas and increased spatial consumables utilization. The company expanded its Simoa menu and released new spatial assays, contributing to growth in neurology biomarker and oncology segments, while also securing new commercial partnerships and insurance coverage for Alzheimer's disease testing in Florida. Despite a year-over-year revenue decline, Quanterix is focused on scaling its diagnostics business, aiming for profitability and cash generation in 2027 with a target of $70 million in cash by year-end 2026 and no debt.

QTRX: Quanterix Corporation filed SEC Form 8-K: Results of...

https://quantisnow.com/insight/quanterix-corporation-filed-sec-form-8-k-results-of-operations-and-6780433
Quanterix Corporation (QTRX) filed an SEC Form 8-K detailing its financial results. The company reported Q3 revenue of $35.0 million, a 13% year-over-year decrease but a 6% quarter-over-quarter increase, and narrowed its FY26 revenue guidance to $142M-$146M, with $81M cash on hand. The filing, published on November 9, 2026, also included information on historical stock performance following previous headlines.

QTRX: SEC Form 10-Q filed by Quanterix Corporation

https://quantisnow.com/insight/sec-form-10-q-filed-by-quanterix-corporation-6780546
Quanterix Corporation (QTRX) filed its Q3 2026 10-Q report, revealing $46.9 million in impairment and restructuring costs for the nine-month period, largely due to writing down goodwill from the Akoya acquisition and an IPR&D asset. While nine-month costs increased, Q3 2026 impairment costs significantly decreased year-over-year. The report also highlighted increases in cost of product and service revenue, partly due to the Akoya business inclusion, and 47.5 million shares outstanding as of November 2, 2026.

Quanterix 3Q 2026: Revenue $34.97M, EPS ($0.46) — 10-Q Summary

https://www.tradingview.com/news/tradingview:8e894a4142b48:0-quanterix-3q-2026-revenue-34-97m-eps-0-46-10-q-summary/
Quanterix reported a 13% year-over-year decline in third-quarter revenue, reaching $34.97 million, primarily due to lower instrument demand and reduced Accelerator Laboratory activity. Despite this, the net loss narrowed by 35.6% to ($21.59M), and diluted EPS improved by 37% to ($0.46), aided by lower operating expenses. The company also highlighted $85.0 million in annualized cost synergies post-Akoya integration and expanded insurance coverage for its blood-based biomarker testing.

A 36% narrower Q3 loss at Quanterix (QTRX) comes alongside a revenue decline.

https://www.stocktitan.net/sec-filings/QTRX/10-q-quanterix-corp-quarterly-earnings-report-d7c98c32b889.html
Quanterix (QTRX) reported a 13% decline in Q3 2026 revenue to $35 million year-over-year, largely due to weaker instrument demand and reduced Accelerator Laboratory services. However, the company narrowed its net loss by 36% to $21.6 million compared to the previous year, with nine-month revenue rising to $104.3 million. Despite a challenging capital funding environment affecting instrument sales, the company is implementing strategic changes, including a reorganized commercial structure and increased focus on Alzheimer's diagnostics, to accelerate revenue growth.
Advertisement

Form 8K Quanterix Corp For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-quanterix-corp-for-9-november-93CH-4943141
Quanterix Corp (QTRX) filed a Form 8K on November 9, 2026. The article from Investing.com announces this filing, noting a significant increase in QTRX's stock price by 12.68%.

Form 8-K Quanterix Corp For: Nov 09

https://www.streetinsider.com/SEC+Filings/Form+8-K+Quanterix+Corp+For%3A+Nov+09/27311792.html
Quanterix Corporation filed a Form 8-K on November 9, 2026, announcing its financial results for the third fiscal quarter ended September 30, 2026. The report includes the Earnings Release and slides to be presented during the company's earnings call on the same date. This information is furnished, not filed, and is not subject to certain liabilities under the Exchange Act.

Quanterix’s Q3 Revenue Declines 13 Percent

https://www.genomeweb.com/business-news/financial/results/gnw-quanterix-q3-results-20261109/
Quanterix reported a 13 percent decline in its third-quarter revenue. The article, published on November 9, 2026, by a staff reporter, details this financial result.

QTRX: Quanterix Corporation filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/quanterix-corporation-filed-sec-form-8-k-results-of-operations-and-6780433
Quanterix Corporation (QTRX) filed an SEC Form 8-K reporting its third-quarter 2026 financial results. The company posted revenue of $35.0 million, a 6.3% increase quarter-over-quarter but a 13% decrease year-over-year. Quanterix also narrowed its full-year 2026 revenue guidance to $142 million to $146 million and updated its year-end cash balance outlook to $70 million.

Quanterix Corporation (QTRX) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/QTRX/seasonality/
The Yahoo Finance page for Quanterix Corporation (QTRX) displays real-time stock information, including its current price, daily change, and after-hours trading data. The page highlights that Quanterix had its Q3 2026 earnings call and provides historical seasonality data, showing average monthly price returns from 2017 to 2026.
Advertisement

Quanterix Corporation (QTRX) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/QTRX/
This article provides a detailed overview of Quanterix Corporation (QTRX), a life sciences company specializing in protein detection platforms and assays for neurology, oncology, and immunology. It includes current stock performance, key financial metrics, analyst ratings, and a company profile. The stock was trading at 3.1550 USD, up 1.12%, as of the market open on October 29, 2026.

Quanterix Corporation Estimates – NASDAQ:QTRX

https://www.tradingview.com/symbols/NASDAQ-QTRX/financials-estimates/
This page on TradingView provides financial estimates and actuals for Quanterix Corporation (NASDAQ:QTRX). Users can explore reported financial data and analyst estimates across the income statement, balance sheet, cash flow statement, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform offers sections for annual and quarterly data, along with a disclaimer about investment advice.

QTRX: Quanterix Corp Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/QTRX
This article provides an overview of Quanterix Corp (QTRX), including its latest stock price, market capitalization, and fundamental data. It details the company's engagement in developing ultra-sensitive digital immunoassay platforms and lists its key products and services. The article also includes recent news releases about Quanterix and a sentiment analysis from a user.

Form 4 Quanterix Corp: Michael Francis Miller (CTO) For: 15 October

https://uk.investing.com/news/stock-market-news/form-4-quanterix-corp-michael-francis-miller-cto-for-15-october-93CH-4915593
This article reports on a Form 4 filing for Quanterix Corp, specifically detailing a transaction by its CTO, Michael Francis Miller, on October 15th. The filing provides transparency on insider trading activities for the company (QTRX).

Form 4 Quanterix Corp: Michael Francis Miller (CTO) For: 15 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-quanterix-corp-michael-francis-miller-cto-for-15-october-93CH-4509785
The article reports on a Form 4 filing for Quanterix Corp, specifically detailing a transaction by its CTO, Michael Francis Miller, on October 15. The brief piece indicates that the information was published by Investing.com. It also includes market data and popular news headlines as ancillary content.
Advertisement

Form 4 Quanterix Corp: Michael Francis Miller (CTO) For: 15 October

https://au.investing.com/news/stock-market-news/form-4-quanterix-corp-michael-francis-miller-cto-for-15-october-93CH-4696323
This article reports on a Form 4 filing for Quanterix Corp, detailing a transaction involving Michael Francis Miller, the company's CTO, on October 15th. The filing indicates a change in ownership for a key executive at Quanterix Corp (QTRX).

1,558 stock awards convert into shares for Quanterix (QTRX) technology chief Michael Francis Miller.

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-e7926342a596.html
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, converted 1,558 restricted stock units (RSUs) into common stock on October 15, 2026. Separately, 467 shares were delivered or withheld for tax liability at $3.07 per share. These conversions are part of several RSU grants with a vesting schedule of 25% on the first anniversary and the remaining 75% in 36 equal monthly installments.

TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Raises Target Price to $3.5

https://www.moomoo.com/news/post/1001048253/td-cowen-maintains-quanterix-qtrxus-with-hold-rating-raises-target
TD Cowen has reiterated its Hold rating on Quanterix (QTRX.US) and increased the target price for the stock to $3.5. This indicates a maintained neutral outlook on the company's stock performance while acknowledging a slight uplift in its valuation prospects.

China approves blood-test kits for four Alzheimer’s-related markers

https://www.stocktitan.net/news/QTRX/quanterix-and-innovita-expand-ivd-access-in-china-with-national-x8fiuwtjgzjr.html
Quanterix and Innovita Biological Technology have received regulatory approvals from China's National Medical Products Administration (NMPA) for Quanterix's SIMOA® instruments and four neurology biomarker testing kits in China. These approvals, covering p-Tau 217, GFAP, p-Tau 181, and NfL, will expand access to ultra-sensitive blood-based Alzheimer's disease diagnostic testing in the Chinese market. This partnership aims to support earlier and more informed clinical decision-making for Alzheimer's disease through advanced diagnostics.

Quanterix and Innovita Secure China Regulatory Approvals for SIMOA-Based Alzheimer's Disease Biomarker Tests

https://biopharmaapac.com/news/97/8539/quanterix-and-innovita-secure-china-regulatory-approvals-for-simoa-based-alzheimers-disease-biomarker-tests.html
Quanterix Corporation and Innovita Biological Technology Co., Ltd. have received regulatory approvals in China for Quanterix's SIMOA technology and four neurology biomarker assays. These approvals, granted by China's NMPA, include the HD-X and SR-X instruments and tests for p-Tau 217, GFAP, p-Tau 181, and NfL, significantly expanding access to ultra-sensitive blood-based diagnostics for Alzheimer's disease in the Chinese market. This partnership aims to facilitate earlier and more informed clinical decision-making for Alzheimer's disease patients.
Advertisement

Quanterix and Innovita win China approval for Alzheimer's blood tests

https://www.streetinsider.com/Corporate+News/Quanterix+and+Innovita+win+China+approval+for+Alzheimers+blood+tests/27158298.html
Quanterix and Innovita Biological Technology have received approval from China's National Medical Products Administration (NMPA) for Quanterix's HD-X and SR-X instruments and four neurology biomarker testing kits. These tests, utilizing Quanterix's Simoa technology, target proteins associated with Alzheimer's disease pathology, neurodegeneration, and neuroinflammation, enabling earlier and more informed clinical decision-making in China. This approval marks a significant step in expanding access to ultra-sensitive protein biomarker testing globally through their 2024 commercialization agreement.

ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research

https://uk.finance.yahoo.com/news/alzpath-quanterix-expand-strategic-licensing-123000030.html
ALZpath and Quanterix have expanded their strategic licensing agreement to further Alzheimer's disease biomarker research. This expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, which has been widely utilized in neurodegenerative disease research since their initial 2023 agreement. The collaboration aims to advance blood-based diagnostic solutions for Alzheimer's by combining ALZpath's high-performance antibodies with Quanterix's sensitive analytical technologies.

Quanterix Receives Chinese Regulatory Approvals, Inks Expanded Licensing Deal With Alzpath

https://www.genomeweb.com/diseases/neurological/alzheimers/gnw-quanterix-alzpath-innovita-china-20261007/
Quanterix has secured Chinese regulatory approvals and expanded its licensing agreement with Alzpath. The company's achievements include significant market penetration in China and a strengthened partnership for Alzheimer's disease diagnostics. This development highlights Quanterix's growth in global markets and its commitment to advancing diagnostics.

Quanterix stock fell 9.06 percent as Q2 reset weighs

https://www.ad-hoc-news.de/boerse/news/nebenwerte/quanterix-stock-fell-9-06-percent-as-q2-reset-weighs/70249173
Quanterix stock (QTRX) fell 9.06% to USD 3.46 on October 6, 2026, after its Q2 2026 revenue of USD 32.9 million missed analyst estimates and the company lowered its full-year 2026 revenue guidance. The stock is now 60.49% below its 52-week high, with analysts maintaining a cautious outlook and an average target price of USD 3.00.

A director converts awards into 4,224 shares at Quanterix (QTRX), bringing her holdings to 15,883 shares.

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-3e2a8f5343eb.html
Quanterix director Ivana Magovcevic-Liebisch converted 4,224 restricted stock units (RSUs) into common shares on October 2, 2026. This transaction increased her direct common share holdings to 15,883, while she now holds 4,352 restricted stock units. The RSUs were part of a 12,800-unit grant from October 2, 2024, with a vesting schedule over three years.
Advertisement

A 4,398-share grant replaces Q3 cash fees for Quanterix (QTRX) director Scott Mendel.

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-32634f2a16f8.html
Quanterix Corp. director Scott Mendel received a grant of 4,398 common shares on October 1, 2026, in lieu of cash fees for his board and committee service during the third quarter of 2026. This transaction increased his direct common-stock position to 28,454 shares, with the reported per-share amount being $3.41. The filing, categorized as neutral in impact and sentiment, details the stock grant as a compensation method for his services.

For Q3 board service, Quanterix (QTRX) grants director Donnelly 6,964 shares instead of cash.

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-633defe2554b.html
Quanterix Corp director William P. Donnelly received 6,964 shares of common stock on October 1, 2026, priced at $3.41 per share, in lieu of cash fees for his third-quarter 2026 board and committee service. This transaction increased his direct holdings to 169,365 shares. The filing, categorized as a Form 4, indicates a neutral impact and sentiment according to Rhea-AI.

Spatial proteomics panels advance with Quanterix at ESSB 2026

https://www.labmanager.com/spatial-proteomics-panels-advance-with-quanterix-at-essb-2026-36051
Quanterix Corporation is launching three new spatial proteomics programs at the European Society for Spatial Biology (ESSB) meeting, moving them from preview to commercial availability. These include the global release of the PhenoCode Molecular Barcoding Kit, the Q4 2026 shipment of two new PhenoCycler-Fusion content panels for Tumor Immune Microenvironment (TIME) and high-plex ADC analysis, and the opening of its Accelerator Laboratory for custom antibody-drug conjugate (ADC) panel development requests under clinical quality frameworks. These advancements aim to address key challenges in high-plex spatial proteomics, such as customizing panels and integrating ADC target expression with immune contexture for translational and clinical research.

Quanterix Advances Spatial Biology Content Innovation

https://www.technologynetworks.com/cancer-research/product-news/quanterix-advances-spatial-biology-content-innovation-417002
Quanterix announced significant advancements in its Content Innovation Engine for spatial biology, with new updates revealed at the European Society for Spatial Biology (ESSB) meeting. The company has released its PhenoCode™ 2.0 Molecular Barcoding Kit and plans to ship the TIME panel and a high-plex ADC panel in Q4 2026. Additionally, Quanterix's Accelerator Laboratory Services are now offering custom ADC panel development for biopharma and translational teams.

Quanterix Corporation (QTRX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/QTRX/
This article provides a detailed overview of Quanterix Corporation (QTRX), a life sciences company specializing in medical devices and diagnostics. It includes current stock performance, key financial metrics, company overview, recent news, performance against benchmarks, earnings trends, analyst insights, and valuation statistics. The company's stock is currently trading at $3.44, up 5.20%, with a market capitalization of $162.688 million.
Advertisement

365,326 stock units go to two new employees at Quanterix. They vest over four years.

https://www.stocktitan.net/news/QTRX/quanterix-corporation-reports-inducement-grants-under-nasdaq-listing-wpbir2ntqmlr.html
Quanterix (NASDAQ: QTRX) announced inducement grants of restricted stock units (RSUs) to its new Chief Commercial Officer, James Gute, and two other employees. Mr. Gute received 260,315 RSUs, and the other two employees collectively received 365,326 RSUs. These RSUs will vest in four equal annual installments and were granted under the company's 2025 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).

Quanterix Corp (NASDAQ: QTRX) Grants 260,315 Derivative Securities to Chief Commercial Officer Gute James Edward Jr.

https://kalkinemedia.com/us/news/announcements/quanterix-corp-nasdaq-qtrx-grants-260315-derivative-securities-to-chief-commercial-officer-gute-james-edward-jr
Quanterix Corp (NASDAQ: QTRX) awarded 260,315 derivative securities to its Chief Commercial Officer, Gute James Edward Jr., on September 15, 2026. This transaction increased his total derivative holdings to 260,315 securities, representing 100% of his updated derivative securities position in the company. The award is classified under code A, indicating an award or grant, and constitutes the entirety of his derivative securities holding in Quanterix.

Quanterix (QTRX) awards its CCO 260K RSUs

https://www.stocktitan.net/sec-filings/QTRX/form-4-quanterix-corp-insider-trading-activity-08d6adb47a09.html
Quanterix (QTRX) has awarded its Chief Commercial Officer, James Edward Gute Jr., 260,315 restricted stock units (RSUs). These RSUs will vest in four equal annual installments over four years, contingent on his continued employment. This grant aligns the executive's compensation with long-term service and company performance.

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://finance.yahoo.com/healthcare/articles/quanterix-corporation-reports-inducement-grants-010000651.html
Quanterix Corporation announced inducement grants to its newly appointed Chief Commercial Officer, James Gute, and two other employees. Mr. Gute received 260,315 restricted stock units (RSUs), while the other two employees collectively received 365,326 RSUs. These grants, approved by the Compensation Committee, vest over four years and are intended to be an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Quanterix Names Yuri Fesko Chief Medical Officer as Diagnostics Business Expands

https://www.citybiz.co/article/902290/quanterix-names-yuri-fesko-chief-medical-officer-as-diagnostics-business-expands/
Quanterix Corporation has appointed Dr. Yuri Fesko as its chief medical officer to spearhead the expansion of its diagnostics business. Fesko will provide medical and clinical leadership, focusing on the broader market launch of the Lucent AD® Complete Alzheimer’s disease test and advancing regulatory work for the HD-X instrument. His extensive background in clinical affairs and precision medicine, particularly from his previous role at Quest Diagnostics, is expected to be instrumental in commercializing Quanterix's biomarker technologies into clinical applications and regulated diagnostic products.
Advertisement

Quanterix CTO Michael Francis Executes 1,558 Stock Options and Forfeits 467 Shares on September 15, 2026

https://kalkinemedia.com/us/news/announcements/quanterix-cto-michael-francis-executes-1558-stock-options-and-forfeits-467-shares-on-september-15-2026
Quanterix CTO Michael Francis exercised options for 1,558 shares and forfeited 467 shares on September 15, 2026. These transactions updated his total holdings to 38,701 shares before forfeiture and 38,452 shares after, with 24,189 derivative securities remaining. The forfeited shares were valued at $2.72 per share, and the forfeitures were marked with transaction code F, indicating shares withheld for taxes or exercise prices.

Quanterix appoints Yuri Fesko as chief medical officer By Investing.com

https://ng.investing.com/news/stock-market-news/quanterix-appoints-yuri-fesko-as-chief-medical-officer-93CH-2694494
Quanterix Corporation has announced the appointment of Dr. Yuri Fesko as Chief Medical Officer. In this role, Fesko will provide medical and clinical leadership across various departments, especially as the company prepares to launch its Lucent AD Complete five biomarker test for Alzheimer’s Disease. Fesko previously served as Chief Medical Officer at Quest Diagnostics and brings extensive experience in precision medicine strategies.

Quanterix appoints Yuri Fesko as chief medical officer

https://www.investing.com/news/company-news/quanterix-appoints-yuri-fesko-as-chief-medical-officer-93CH-4899456
Quanterix Corporation (NASDAQ:QTRX) has appointed Dr. Yuri Fesko as its new Chief Medical Officer. Dr. Fesko will lead medical and clinical initiatives across various departments as the company prepares to launch its Lucent AD Complete five biomarker test for Alzheimer's Disease. He brings extensive experience in precision medicine and advanced diagnostics from his previous role as CMO at Quest Diagnostics.

Quanterix Corp (QTRX) Earnings, Actual EPS, EPS Estimates & Results

https://stocktwits.com/symbol/QTRX/earnings
This article provides an overview of Quanterix Corp's (QTRX) earnings, including upcoming estimates and historical performance. It details estimated EPS and revenue for Q3 '26, as well as actual reported EPS, estimates, and surprise percentages for previous quarters. The data indicates a mix of missed and beaten EPS estimates in recent fiscal periods.

Bruker Corporation Executive is Named Finance Chief at Quanterix

https://www.mpo-mag.com/breaking-news/bruker-corporation-executive-is-named-finance-chief-at-quanterix/
Quanterix Corporation has appointed Jason Faessler, formerly of Bruker Corporation, as its new chief financial officer. Faessler's extensive experience in finance leadership within the life science tools industry is expected to be crucial for Quanterix's future growth. He previously held senior financial roles at PAREXEL, EMC (now Dell), and Harvard Business Publishing.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement